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Abstract 
Candida species are isolated with high frequency in cystic fibrosis yet their definitive role in 
disease remains unclear. Previously considered to have minimal inherent virulence owing to 
their commensal ability, the last decade has heralded an increasing recognition of Candida 
infection among patients with cystic fibrosis. What has been more recently hypothesized is 
that the organism possesses virulence factors that play diverse roles at different body sites 
during varied stages of an infection. Currently, limited data is accessible in the area of cystic 
fibrosis. This review aims to provide an overview of the role of Candida species in cystic 
fibrosis as is currently understood including the common local and systemic infections 
observed in clinical practice. The uncertain role of airway colonization and insight into 
emerging fields such as Candida-bacterial interactions are also addressed. Finally, we  outline 
the current understanding of the innate, cellular and humoral immune responses associated 
with this genus which has been the major focus of work performed to date.    
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1. Introduction 
 
Major advances in the care of cystic fibrosis (CF) patients have positively influenced 
prognosis over the last decade. Significant inroads into understanding the basic defect have 
accelerated the development of targeted therapies. The disease however continues to present 
new challenges to clinicians and researchers, for example fungal airway colonization. The 
consequences of bacterial infection, colonization and need for segregation in outpatient 
clinics have all been confronted and curbed to the point that fungal colonizers with an 
undetermined role on disease course and progression are becoming increasingly prevalent. 
Both yeasts and filamentous fungi have been identified as microbial pathogens in CF 
particularly in the context of invasive disease in the transplanted population and allergic 
responses, for instance allergic bronchopulmonary aspergillosis (ABPA). One particular 
fungal genus isolated at high frequencies from sputum culture is Candida and limited 
literature is available addressing the issues of Candida colonization and infection in CF. This 
is possibly because its manifestations are still considered relatively minor in comparison to 
other infectious agents. As a consequence it has received little attention in terms of clinical 
and scientific research. This review aims to provide an overview and our current 
understanding of the Candida species in CF, its associated local and systemic infections and 
an insight into emerging data on its role in airway colonization and associated immune 
response.    
 
2. The Candida genus 
Oral thrush was the first infection of the Candida species described in humans and following 
identification of its reproductive potential by budding, the fungus was originally named 
Oidium albicans. Candida albicans became the adopted name used and since then many 
other species have been identified to play a role in human infection.  The most common of 
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these are Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis and 
Candida tropicalis (1, 2).  
 
The genus has exponentially grown with hundreds of newer member species identified and 
unlike dimorphic fungi the morphology of a given Candida species remains fundamentally 
comparable in vitro or vivo. Candida species are capable of causing chronic, localized or 
systemic infection collectively termed ‘candidiasis’ although most commonly act as 
commensals within the oropharynx, skin folds, gastrointestinal tract and vagina.  On occasion 
it can cause opportunistic infection (3). Once infection ensues, significant morbidity and 
mortality results and consequently, systemic candidiasis has high death rates (>75%) (4).  
 
Identification in the microbiology laboratory is achieved on Sabouraud dextrose media and 
Candida albicans can be identified through germ tube testing or colorimetric detection of L-
proline aminopeptidase and beta-galactosaminidase. Since recent isolation of Candida 
dubliniensis which produces false positive results in the above tests, a chromogenic agar 
culture method that allows isolation and identification of Candida albicans, Candida 
tropicalis and Candida krusei has been widely adopted. A modified version of this media is 
available to more clearly distinguish Candida dubliniensis (5). Alternative older methods to 
distinguish between the two organisms include an assessment of growth ability at higher 
temperatures (45˚C for Candida albicans) or specific DNA sequencing.    
 
Patients with CF are at an increased risk of acquiring Candida due to use of inhaled steroids, 
diabetes mellitus and lifelong antibiotic treatment however despite its frequent isolation from 
sputum, oral and vaginal swabs, it remains unclear what such culture actually means in 
practical terms for CF clinicians. We believe that a spectrum of “commensal-colonizer-
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pathogen” most likely exists for the organism and where specifically the organism is on this 
spectrum at a particular time point may be dictated by the clinical state of the CF patient and 
whether bacterial co-colonizers are concurrently present in the airway.  
 
Prior studies have addressed the notion that although frequently identified in CF, the clinical 
role of Candida species has yet to be definitively determined (6-8). Bakare et al identified 
Candida as the second most frequent fungal growth to Aspergillus in the CF airway and such 
growth has been associated with more severe CF where patients receive prolonged treatment 
with antibiotics, glucocorticoids and probiotics (9-12). In terms of infection, Cimon et al 
performed a five-year epidemiological study assessing the frequency of bronchopulmonary 
mycoses in a CF population and examined the aetiological role of individual fungal species in 
disease. The filamentous fungi Aspergillus and Scedosporium apiospermum together with 
Candida contributed the largest burden. Despite high isolation of Candida in CF, a single 
case of candidiasis was observed and this low rate was attributed to the anti-fungal ability of 
various bacterial colonizers in CF and whilst invasive airway infection is a rare event, extent 
of airway damage from hypersensitivity phenomena remain unknown (13). We will now 
address the localized and systemic infections associated with Candida species in CF and 
subsequently tackle the complex issues of airway colonization, cross kingdom interaction and 
the immune response. 
       
3. Localized Candida infection in CF 
3.1 Oral candidiasis 
Candida species are isolated from the oral mucosa in up to 40% of healthy adults and 
therefore considered commensal (14). A cut-off point to distinguish between commensalism 
and colonization remains undetermined. Common risk factors associated with oral recovery 
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include poor dentition, older age, diabetes mellitus, use of inhaled or systemic steroids, 
smoking, malignancy and frequent antibiotic use. Oral thrush usually presents as discomfort 
associated with a dry mouth and associated dysphagia. In some cases, altered taste is 
experienced. The diagnosis is usually straightforward and by direct observation of white 
membraneous plaques on the buccal mucosa or soft palate. This may be confirmed 
microbiologically by staining a swab or culturing a rinse from the associated area. Atypically, 
foci of oral erythematous inflammation or angular cheilitis may present. There are clearly 
significant risk factors in the CF state that predispose to oral colonization and subsequent 
infection including impaired salivary secretion, steroid use, CF-related diabetes and recurrent 
courses of antibiotics for exacerbations. Antibiotics alter the homeostasis of oral flora and as 
such have a permissive action on Candida growth. In a study from Manchester, on direct 
questioning of major symptoms in the CF population, 40% (n=17) complained of a sore 
mouth, 24% (n=10) of thrush five times annually and 38% (n=16) of a hoarse voice every 
three months (15). In our own institution’s experience, we encounter regular instances of oral 
candidiasis annually following courses of antibiotics but which resolve after a short burst of 
anti-fungal treatment (Fluconazole). We recommend microbiological confirmation by 
scrapings in all cases unless white plaques are directly observed on oral examination. This is 
because some of the symptoms described are not specific to oral thrush but can be found in 
associated vitamin deficiencies (B6, B12) or by simple blistering. We recommend that CF 
patients attending routine clinic be screened for risk factors and questioned at three-monthly 
intervals with regard to the symptoms of oral thrush including frequency of sore or dry 
mouth, crusting lips, dysphagia, dysphonia or hoarseness and difficulties with taste. Any 
relationship to antibiotic treatment should be teased out. Clearly oral candidiasis is 
recognized in CF but the dearth of available literature suggests it is probably misdiagnosed, 
ignored or missed in several cases. A simple risk factor and symptom screen would see 
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improvements both in quality of life and probably compliance with other CF treatments. With 
the advent of newer and increasingly earlier administration of anti-bacterial therapies, oral 
candidiasis is likely to become a more significant issue in the future care of CF patients.   
 
3.2 Genital candidiasis 
Genital candidiasis is a common occurrence in the normal population with rates of up to 75% 
having single and 50% recurrent episodes (2). It may be asymptomatic or present with 
balanitis in males and pruritis with vaginal discharge in females. Most infections are caused 
by Candida albicans (95%) however Candida glabrata (5%) infection is described (2). There 
is limited but important literature available addressing these infections in CF with the 
majority focused on female manifestations. It has been more than a decade since Sawyer et al 
first reviewed the subject with a self-administered questionnaire in young women with CF 
(n=55) (16). Vulvovaginal candidiasis was more common in CF (35%) versus controls (13%) 
and additionally more persistent and difficult to treat. Antibiotic use was a significant 
association and the work concluded that “health professionals generally trivialize illnesses 
and diseases that are common, easily treated and not life-threatening”. More recent work has 
included male patients and addressed symptomatic partners. Lyon et al evaluated 40 adults 
with CF (19 male, 21 female) and similarly found large proportions (62.5%, n=25) 
experiencing symptoms of infection however few (15%, n=6) had been directly questioned 
about it at CF clinic (17). Patients refused to discuss if their partners were symptomatic. This 
highlighted to CF clinicians a major deficiency of clinical practice and questions about 
candidiasis should feature during annual review clinic consultations. It is also important to 
consider that vaginal discharge in young CF women can be caused by other pathogens such 
as Chylamidia, Gonococcus or Trichomonas species and that there is an observed 
unexplained high incidence of genital Chylamidia in CF.   
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A third study addressing the same subject was performed by interview in 101 CF patients and 
addressed symptom frequency and medical risks associated with Candida (18).  Patients were 
asked to report on personal risk factors for Candida infection and their desire to be 
questioned about ‘thrush’ in CF clinic. Many had two or more risk factors (92.1%, n=93) 
however the only significant factor associated with genital Candida was long-term antibiotics 
(87.1%, n=88, p=0.001). Over seventy percent of patients, both males and females had 
symptoms of either oral or genital Candida or both simultaneously. Forty percent (18/45) of 
those with oral and two-thirds (33/50) of those reporting genital candidiasis described 
‘distress’ however it did not affect desire for treatment. Most cases of oral infection were 
diagnosed by a CF physician whilst genital infection was mainly self-diagnosed. It is 
noteworthy that general practitioners diagnosed more cases of genital infection when 
compared to CF physicians. This is potentially explained by differing doctor-patient 
relationships in different settings or alternatively because the focus of the CF unit remains on 
respiratory or gastrointestinal symptoms leading patients to believe that this forum is 
inappropriate for discussing other complaints. Most patients in the study did however want to 
discuss such issues and were unconcerned who their discussant was although some females 
predictably preferred discussion with female staff. This Manchester based study is the largest 
to date and detected similar patterns to previous work. The most concerning new discovery 
was the high incidence of symptoms among CF patients but only on direct questioning 
placing a future onus on CF clinics. A major criticism of all these studies was that symptom 
recording was not supported by microbiological confirmation of infection, an important point 
for future work. Additionally, although several publications have assessed the benefits and 
efficacy of anti-fungal treatment in vulvovaginal candidiasis in the ‘normal’ population, 
importantly none have been performed in CF (19). Despite this clear lack of available 
literature, we strongly recommend screening questions for infection at all CF clinic visits and 
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depending on clinical findings, anti-fungal treatment prescribed either empirically or 
following microbiological confirmation.                 
 
4. Systemic Candida infection in CF 
4.1 Post-transplant Candidiasis 
CF is the 3rd most common indication for lung transplantation and the opportunistic nature of 
Candida species suggest that the post-transplant period is ripe for such infection (20). Despite 
this, candidiasis post-transplant remains rare and Aspergillus species are in fact more 
commonly encountered in this setting (21). The main Candida infection following 
transplantation is surprisingly tracheobronchitis which includes anastomotic site infections. 
Bloodstream and other invasive infections secondary to Candida are rare and will not be 
addressed in any detail within this review except to state that when present occur within the 
first month following transplantation (22, 23). This is primarily a consequence of the major 
surgical intervention and intensive care unit stay experienced by patients.    
   
4.2 Totally implantable venous access device (TIVAD) infection 
A more commonly encountered systemic infection associated with Candida involves the 
presence of a TIVAD commonly referred to as a “port”. Candida species in this setting are 
recognized as the most common infecting organism associated with a TIVAD resulting in 
septicaemia (24-26). Important risk factors for infection remain the same as that for other 
Candida infections. Diagnosed by the presence of swinging pyrexia, systemic septicaemia 
and positive blood cultures for Candida species taken from both the port site and 
peripherally, the first intervention remains to remove the offending device whose tip should 
also be sent for microbiological evaluation. Device removal results in significant clinical 
improvement however aggressive anti-fungal therapy is concurrently administered during 
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which time patients on the active transplant list have to be removed temporarily. Recently, we 
encountered a case series at our centre which presented a different setting to the traditional 
Candida port infection. We experienced three cases of TIVAD thrombosis and superior vena 
cava obstruction that required use of thrombolytic therapy. In two of the three patients, their 
post-thrombolysis course was complicated by systemic candidiasis secondary to TIVAD 
infection. In these cases, we achieved a successful outcome following removal of the device 
coupled with aggressive anti-fungal treatment. Another more traditional case series described 
earlier this decade over a six year period was that from a CF centre in Manchester where 
fifteen adults with CF were diagnosed via positive blood cultures with a Candida port 
infection (15). Here, a variety of Candida isolates were identified including albicans, 
parapsilosis and glabrata and excellent clinical outcomes again achieved via device removal 
and systemic anti-fungal treatment dictated through sensitivity testing. Our own practice 
continues to evolve with regard to optimal treatment and we routinely look for at least two 
negative blood cultures following completion of the prescribed treatment course. Replacing 
ports depends on need but we try not to replace before 8 weeks following the last negative 
blood culture. To date, there remain no clinical trials or evidence based guidelines to support 
these treatment practices. Another important point is that many Candida infections involve 
biofilm formation particularly with indwelling vascular catheters in the context of CF. These 
biofilms are microbiologically complex containing matrix enclosed microcolonies containing 
yeasts and hyphae in a bilayer structure (27). Such Candida biofilms can be resistant to 
conventional anti-fungals through a multitude of mechanisms and as such future research 
needs to be conducted to determine the best and optimally standardized treatment of Candida 
port infections.            
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5. Airway  Candida colonization in CF 
It remains controversial as to whether Candida species are transient or persistent colonizers 
of the respiratory tract in CF. A study by Muthig et al showed that the mean persistence of 
Candida species was at least nine months and that the species identified were genetically 
related and transmissible but susceptible to all anti-fungals tested. Although concerns of 
transmissibility persist, it is unsure whether this species conclusively contributes to chronic 
infection and the inflammatory milieu in CF (28). We have assessed colonization rates at our 
own centre over prolonged time periods and found persistence rates in excess to that 
previously described.  We have established that the main factors predicting colonization by 
Candida albicans in CF are pancreatic insufficiency, osteopenia and co-colonization with 
Pseudomonas.  At first glance, this suggests that the more advanced a patient’s disease, the 
likelier their sputum contained Candida albicans, a view of many clinicians and it may be 
that the organism acts as nothing more than a microbiological marker of disease severity in 
CF. To challenge this paradigm, we are currently prospectively evaluating whether airway 
colonization by Candida albicans may act pathogenically by affecting clinical outcomes in 
CF including FEV1, BMI, hospitalizations for infective exacerbations and sputum 
colonization with Pseudomonas or Aspergillus species. Notably, a previous cross sectional 
analysis of a European CF registry did show that Candida albicans colonization was 
associated with 5-10% predicted decrease in pulmonary function (29).  
 
Newer airway Candida species have also emerged over the last decade and one pertinent 
example is the high recovery rates (10-25%) of C. dubliniensis from the oral cavity of HIV 
patients (30). This new organism was subsequently described in the non-HIV population 
particularly in individuals receiving high antibiotic burdens (31). Therefore, its detection in 
CF came as no surprise but did involve a complex isolation procedure involving Staib agar 
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(32). What was surprising was that its prevalence rate in CF was higher than that found in 
HIV however virtually nothing about its potential for virulence is known. There is no clear 
clinical or experimental evidence of differences in terms of pathogenic potential when 
compared to Candida albicans (33) however Candida dubliniensis is reported to exhibit cell 
surface hydrophobicity not observed in the albicans species (34). Cell surface hydrophobicity 
is known to play a role in the adhesion of microorganisms and by displaying this feature, 
Candida dubliniensis takes advantage of the dehydrated respiratory secretions in CF and 
consequently proliferates. These observations may also explain why patients who are older 
(>30 years) and have more advanced disease are colonized by this yeast. Peltroch et al (32) 
followed six CF patients with Candida dubliniensis and whilst all patients remained stable 
with no invasive infection detected its effect on lung function could not be conclusively 
established because of the small numbers. A larger epidemiological study of this Candida 
species in CF is warranted.          
 
6. Candida-bacterial interactions 
According to Costerton (35), biofilms are ‘a structured community of bacterial cells enclosed 
in a self-produced polymeric matrix and adherent to an inert or living surface’. Traditionally 
biofilms have been thought to comprise a single bacterial species however it is now 
increasingly recognised that mixed biofilms exist involving interactions between both 
prokaryotes and eukaryotes. Bacteria and fungi are found together in a variety of 
environments but particularly in biofilms, where adherent species interact through diverse 
signaling mechanisms. In the host C. albicans can often be found growing with bacteria in 
polymicrobial biofilms and interspecies interactions occur that can impact on the transition of 
C. albicans between virulent and nonvirulent states (27). Under conditions of immune 
dysfunction, such as in the CF lung, colonising C. albicans can become an opportunistic 
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pathogen causing mucosal and disseminated infections potentially impacting on mortality. In 
the biofilm environment, microbial species use 'quorum-sensing' (QS) molecules for cell-to-
cell communication to promote collective behaviour within the population, enhance access to 
nutrients and niches, and provide a combined defense against competitor organisms (36, 37). 
The process of QS can cross the prokaryote–eukaryote boundary (36-39).  
 
6.1 Interactions with Pseudomonas aeruginosa 
Pseudomonas aeruginosa is the most prevalent opportunistic pathogen in individuals with CF 
and is the principal organism associated with biofilm formation in the CF lung; S. aureus and 
Burkholderia spp. are also considered important pulmonary pathogens in CF. The dimorphic 
yeast C. albicans is the most common eukaryotic microbe isolated from CF patient sputum (9, 
10, 40). C. albicans can exist in a mixed biofilm where the prokaryotic and eukaryotic 
communities exhibit either synergistic or antagonistic interactions. Several studies suggest 
that P. aeruginosa and C. albicans interact with each other in vivo, and they are commonly 
found together in mixed infections (41).  In their seminal paper Hogan and Kolter (38) first 
reported a pathogenic relationship between P.  aeruginosa and C. albicans. They 
demonstrated how P. aeruginosa can form a dense biofilm on C. albicans filaments and kill 
the fungus. Interestingly this only occurred when C. albicans was growing in its filamentous 
(or hyphal) form – an essential feature associated with its virulence (42). P. aeruginosa 
neither bound to nor killed the yeast form of C. albicans and the ability of P. aeruginosa to 
kill filamentous C. albicans was dependent on a number of physiological factors including 
growth phase, nutrient availability, surface structures including flagellae and type IV pili, 
secreted QS factors and regulatory molecules such as rpoN (43).  By forming a biofilm on 
fungal filaments P. aeruginosa may be able to obtain nutrients from C. albicans in a 
nutritionally scarce environment. 
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Prior to killing of C. albicans by P. aeruginosa, signalling can occur between both 
organisms. The QS molecules of both species are responsible for this communication. For 
example the bacterial molecule 3-oxo-C12 homoserine lactone can affect Candida 
morphology, whilst the fungal 12-carbon sesquiterpene metabolite, farnesol can interfere with 
Pseudomonas quinolone and pyocyanin production and swarming motility (37, 39, 41, 44-
49).  Thus eukaryotes and prokaryotes possess diverse signaling mechanisms to detect and 
respond to each other through QS signal molecules.  
6.2 Interactions with Staphylococcus aureus 
In oral biofilms a mutually beneficial interaction called coaggregation can occur where the 
adhesion of C. albicans to oral bacteria facilitates its colonization of the oral cavity (50-52). 
In contrast, the interaction between C. albicans and Pseudomonas aeruginosa as described 
above is competitive and antagonistic in nature. A third mechanism of interaction that can 
occur is that evident between staphylococci and C. albicans, which appears to be initially 
synergistic (53-55). Carlson et al. (56, 57) described a synergistic effect between C. albicans 
and S. aureus in a mouse infection model leading to enhanced mortality following dual 
infection suggesting that C. albicans can either enhance the virulence of S. aureus or impair 
the host’s immune defences. Extensive physical interactions are known to occur between S. 
aureus and both the yeast and hyphal forms of C. albicans in a mixed biofilm (58) and it has 
been suggested that farnesol has a role in orchestrating these interactions. After the initial 
synergy during C. albicans-S. aureus biofilm formation farnesol then negatively affects 
staphylococcal biofilm formation, compromises cell membrane integrity, viability and 
susceptibility of S. aureus to a variety of clinically important antibiotics (58). Thus farnesol 
may represent a therapeutic target for inhibiting the development of a mixed biofilm in the 
CF lung however once the biofilm has been established farnesol may actually behave as an 
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anti-bacterial factor. It remains to be seen which has the more detrimental effect in the CF 
lung, C. albicans growing alone or in combination with S. aureus in a mixed biofilm. 
6.3 Interactions with other microbes 
Notwithstanding the ability of C. albicans to modulate bacterial growth, reciprocal evidence 
indicates that other bacteria may also play an important role in the pathogenesis of C. 
albicans infections. For example in the urinary tract Escherichia coli can enhance adhesion of 
C. albicans to bladder mucosa (59) whereas in the gut indigenous microbes can inhibit 
mucosal adhesion of C. albicans (60). Consequently alterations in the normal bacterial flora 
following treatment with broad-spectrum antibiotics may allow C. albicans to proliferate and 
invade tissues, greatly affecting its pathogenicity (60). This is an important consideration for 
individuals with CF who are frequently prescribed antibiotics. 
This may be most clearly studied in the oral cavity where adhesion of C. albicans to saliva-
coated surfaces and proline-rich proteins is an important early step in colonization (50, 61-
63). Many species of oral bacteria may compete with C. albicans for primary adhesion 
receptor sites (50, 61, 64, 65) however once resident in the mouth C. albicans can adhere to 
the major microbial constituents of early dental plaque. 
Similar to P. aeruginosa, another opportunistic pathogen Acinetobacter baumannii exhibits a 
predilection for C. albicans filaments and can inhibit C. albicans filamentation, resulting in 
attenuated virulence of C. albicans in the nematode. Interestingly, similar to its effect on S. 
aureus, C. albicans can also inhibit A. baumannii growth via farnesol production (66). As 
mixed bacterial–fungal biofilms have been shown to be associated with a multitude of 
infections including those affecting endotracheal tubes, biliary stents, silicone voice and 
orthopedic prostheses and acrylic dentures (35, 67) determining the exact sequence of events 
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involved in the development of these mixed biofilms may determine how and when to target 
the individual microbial or fungal constituents.   
 
7. Candida and the immune response 
The outer strata of Candida species contain elements with antigenic potential. These include 
mannans and mannoproteins which upon human exposure induce an immunogenic response 
(68-71). Where mannan-deficient, Candida strains are clinically less virulent and during the 
course of a Candida infection, cellular, humoral and innate immune responses all play a role 
(69, 70, 72-74).  
 
7.1 Innate immunity 
Recognition of microbes by the innate immune system depends on activation of specific 
pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs). 
For fungi the first PAMPs encountered by the immune system are those present in the fungal 
cell wall. The cell wall of Candida albicans is composed of a core structure of β-(1,3)-glucan 
polysaccharide fibrils covalently linked to chitin (a β-(1,4)-linked polymer of N-acetyl 
glucosamine) and β-(1,6)-glucan. The outer layer consists of N-linked (75) or O-linked 
mannosylated proteins called mannans (76). Two classes of PRRs in particular play an 
important role in antifungal immunity - the C-type lectin receptors (CLRs) and Toll-like 
receptors (TLRs). Neutrophils, monocytes, macrophages and airway epithelial cells are all 
involved in defense against fungal pathogens. Dendritic cells (DCs) also respond to fungal 
PAMPs leading to activation of T-cell-mediated specific immunity. These various cell 
populations differ in their expression of CLRs and TLRs on the cell membrane, and are 
therefore capable of initiating different responses. CLRs and TLRs recognize the major 
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polysaccharide cell wall components, N- and O-linked mannans, β-mannosides, β-(1,6)-
glucan and phospholipomannan.  The mannan structures are detected by the mannose 
receptor (MR), the dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN), dectin-2, 
galectin-3 and TLR4 whereas complement receptor 3 (CR3), dectin-1 and TLR2 detect the β-
glucans.   
7.1.1 CLRs 
CLRs comprise a large family of receptors that share at least one carbohydrate 
recognition domain originally identified in mannose binding lectin (MBL). CLRs are 
evolutionary conserved and have been shown to be involved in the modulation of the innate 
immune response and fungal recognition. Although MBL can bind to C. albicans (77) and 
has the ability to opsonize fungal yeasts by activating the complement system (78), MBL-
deficient mice do not show decreased survival to infection with C. albicans (79). However 
dectins-1 and -2, galectin-3, DC-SIGN and MR do play important roles in the innate immune 
response to C. albicans.  
Dectin-1 recognizes β-(1,3)-glucans, mediates ligand uptake and phagocytosis, and 
triggers cytokine production (80). Alone it is sufficient in inducing responses to fungi 
however synergistic proinflammatory responses occur in cooperation with TLRs. For 
example in collaboration with TLR2, dectin-1 triggers proinflammatory responses by C. 
albicans or zymosan (81, 82). Dectin-2 is mainly expressed on myeloid cells and maturing 
monocytes. It recognizes high-mannose structures (83) and interacts with the FcγR to induce 
TNF in response to filamentous C. albicans (84). On macrophages the galectin-3 receptor 
mediates the recognition β-mannosides expressed on C. albicans. This PAMP-PRR 
interaction is also enhanced by TLR2 (85). DC-SIGN, expressed on mature DCs, recognizes 
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high-mannose structures in C. albicans and mediates phagocytosis of fungal particles (86). 
Finally, MR recognizes chitin, fucose, and mannose and has been implicated in the 
recognition of several fungi, including C. neoformans, C. albicans, and Pneumocystis. 
Branched N-bound mannans in C. albicans are recognised by MR (87) and mice defective in 
MR display partial impairment in their host defense against Candida infections (88).  
Modulation of CLR expression and activity thus represent important therapeutic 
targets in CF that remain, as yet, underexplored. A newly identified CLR, Mincle, has been 
shown to participate in macrophage recognition of C. albicans. Although it remains to be 
shown which PAMP expressed by C. albicans directly activates Mincle, the role of this 
receptor in fungal innate immunity has been clearly demonstrated. Inhibition studies have 
shown decreased TNF production by macrophages following stimulation by Candida yeast 
cells and Mincle knockout mice display hypersusceptibility to Candida infection (89). It will 
be interesting to determine the expression and function of Mincle by immune cells and 
airway epithelium in individuals with CF.  
7.1.2 TLRs 
Following the initial observation by Lemaitre et al. (90) that Drosophila melanogaster 
flies deficient in the Toll receptor succumb readily to infection with Aspergillus fumigatus 
due to defective synthesis of the drosomycin defensin, the role for TLRs in antifungal defense 
has been extensively studied and recently a human homolog of drosomycin called 
drosomycin-like defensin has been described. This peptide is expressed mainly in the skin 
and has activity against a variety of filamentous fungi (91), however its potential as an 
antifungal or anti-C. albicans therapeutic has not yet been exploited. Early studies on TLRs 
revealed that TLR2 and TLR6 co-operate in recognition of the fungal structure zymosan 
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derived from Saccharomyces cerevisiae (92). With respect to C. albicans, blocking of TLR2 
has been shown to lead to decreased monocyte production of TNF and IL-1β after stimulation 
with C. albicans (93). Furthermore TLR2−/− mice have decreased TNF and MIP-2 production 
and reduced neutrophil recruitment after challenge with Candida (94). TLR1 and TLR6, two 
receptors capable of forming heterodimers with TLR2, may also have a minor role in C. 
albicans recognition (95). Further evidence for an anti-fungal role for TLR2 comes from 
studies showing that TLR2-deficient macrophages have an increased ability to contain C. 
albicans (96),  and that TLR2 signalling  can promote Th2-type or T-reg-type responses in 
response to C. albicans (97, 98).  
TLR4 participates in antifungal host defense by recognizing O-linked mannan 
structures and mediating proinflammatory responses. TLR9 has the potential to recognize 
fungal DNA and blocking TLR9 either pharmacologically in human monocytes or genetically 
in TLR9-deficient mouse macrophages leads to a reduced production of cytokines, mainly 
IL-10, in response to stimulation with C. albicans (99). However the contribution of TLR9 to 
fungal recognition is not believed to be significant. Much is known regarding the expression 
and function of TLRs in the CF lung and is beyond the scope of this article. Readers are 
directly elsewhere for comprehensive reviews of the role of TLRs in CF (100, 101). 
Recognition of C. albicans by the innate immune system therefore occurs through 
MR and DC-SIGN recognizing branched N-linked mannans, and TLR4 recognizing linear O-
linked mannans.  CR3 responds to β-(1,6)-glucan and dectin-1 and galectin-3 in combination 
with TLR2 each recognize β-glucan/phospholipomannan and β-mannosides, respectively. It 
is likely that these recognition receptors can operate in combination and that stimulation via 
multiple PAMP–PRR combinations might increase both the sensitivity and the specificity of 
the immune recognition process. Notwithstanding these elegant recognition systems, C. 
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albicans frequently colonizes individuals with CF. Exactly why C. albicans is so commonly 
found in CF individuals remains to be determined but may be associated with impairment in a 
particular component of the innate immune system. 
7.2 Cell mediated immunity  
Individuals whose cell mediated immunity is compromised are at an increased susceptibility 
of infection with Candida species illustrating the important role that this arm of the immune 
system plays in the host defence against the organism. The reasons underlying this 
observation remain ambiguous and little work has been performed in CF to examine this 
potential link. In non-CF animal models, interleukin (IL)-12 promotes a Th1 response to 
Candida exposure and IL-10 systemic infection (102, 103).  In contrast interferon (IFN)-
gamma appears to be protective (104). Allard et al have shown that CF oropharyngeal 
exposure to Candida lysates evoked a Th2 type immune response similar to that observed in 
non-CF models. However when exposed to both Pseudomonas and Candida lysates together 
a deviation in the adaptive immune response from a Th2 to Th1 type associated with 
neutrophilia is noted (105).  Neutrophils also damage pseudohyphae in association with IFN-
gamma to provide another host resistance strategy against Candida species. This is mediated 
through granulocyte colony stimulating factor (G-CSF) (106, 107). Additionally, Dectin-1 by 
distinguishing cell wall β-glucan can trigger cell mediated defences (81). While the cytokine 
mileu and neutrophil response in CF continue to be an area of intense investigation among 
researchers, minimal data to date remains accessible with regard solely to Candida species.  
 
7.3 Humoral immunity  
 The role of the humoral immune response during Candida exposure and infection remain 
controversial. Despite this, the majority of literature with regards to Candida in CF exists in 
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this area. In the late 1980s, Przyklenk et al first assessed serum IgG antibodies to both 
Aspergillus funigatus and Candida albicans in CF versus control patients and found that 
antibody levels were higher in CF irrespective of sputum isolation (108). In contrast to 
Aspergillus fumigatus, antibodies to Candida albicans were observed to increase significantly 
with increased isolation from sputum culture. Minimal work followed until Maiz et al 
assessed the prevalence of Aspergillus and Candida species in CF sputa and the serologic IgE 
responses to these fungi. For the first time, they additionally investigated whether the 
immune response had direct effects on clinical status in CF (109). Candida species were 
isolated in nearly half of all sputum samples analyzed (47.5%) however 87.9% of patients 
had at least one growth of Candida albicans during the study course. One-quarter (26.7%) 
were sensitized to Candida albicans and only patients who grew Candida albicans at least 
once during the study developed an IgE response to the fungi. The clinical parameters 
assessed (FEV1 and CT scores) were not worse in those sensitized versus the non-sensitized. 
Interestingly, half of the sensitized group had confirmed ABPA whilst the remaining patients 
some immunologic characteristics of ABPA. In conclusion, the group found a high 
prevalence of both colonization and sensitization to Candida albicans in CF but could not 
relate this to disease severity or clinical status. Although serum IgE to Candida albicans 
appeared to represent an immunological marker of ABPA in CF, it is important to note that 
the studied group was small (n=20) and only FEV1 and CT scores assessed as clinical 
measures. The same group extended this work recently to assess serum IgG, IgA and IgM 
against Aspergillus fumigatus and Candida albicans and found that although no correlation 
was detected between the presence of Aspergillus fumigatus in sputum and an immune 
response, the converse was true of Candida albicans. Increasing sputum isolation heralded an 
elevated serum response however again this could not be related to respiratory impairment 
(110). 
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8. Conclusion and future directions 
In this review, we have highlighted the current knowledge base and infections caused by the 
Candida species in CF. The dearth of CF-specific literature available illustrates that it 
evidently is a ‘road less travelled’. Despite this lack of literature and audit, what remains 
undoubted is that the species is isolated frequently and has importance in contributing to 
morbidity and in some cases mortality in CF. There is a high rate of undetected symptomatic 
oral and genital infection in the adult CF population and the problem should not be ignored 
with newer anti-bacterial agents on the horizon that will likely select out these fungal 
pathogens. Long-term use of antibiotics has recurrently emerged as a contributing factor to 
Candida infection and an alteration of flora post therapy lends survival advantages to the 
pathogenicity of this species. In doing so, Candida probably contributes to the inflammatory 
mileu observed in CF. Although post-transplant candidiasis is a rare occurrence, port 
infections do occur frequently. When a port is infected, it should be removed promptly and 
combined with anti-fungal therapy results in excellent clinical outcomes. The Candida 
species interestingly elicits innate, cellular and humoral immune responses that we have yet 
to fully understand in the context of CF. Clearly an increasing amount of work remains left to 
be done to address the many unanswered questions. Future avenues for focus in this field lie 
within clinical care, isolation techniques and biomedical research. Healthcare professionals 
should maintain a positive approach in looking for manifestations of Candida infection 
during annual review at CF clinics and subsequently pursue microbiology in symptomatic 
cases. In terms of isolation techniques, selective media needs to be developed to suppress the 
growth of gram negative pathogens such as Pseudomonas and Burkholderia species and 
enhance fungal identification and isolation. Standardization of detection protocols needs to be 
pursued for fungi in CF as currently lab and international variation persists. Finally, basic 
science and clinical research avenues with regard to Candida species in CF need to be 
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actively pursued so as to enable an improved understanding of its role in the CF airway, 
Candida-bacterial interaction and its potential use as a microbiological marker of CF disease 
severity and progression.      
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